These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 19788498)

  • 1. Oral bioavailability and brain penetration of (-)-stepholidine, a tetrahydroprotoberberine agonist at dopamine D(1) and antagonist at D(2) receptors, in rats.
    Sun Y; Dai J; Hu Z; Du F; Niu W; Wang F; Liu F; Jin G; Li C
    Br J Pharmacol; 2009 Nov; 158(5):1302-12. PubMed ID: 19788498
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The antipsychotic potential of l-stepholidine--a naturally occurring dopamine receptor D1 agonist and D2 antagonist.
    Natesan S; Reckless GE; Barlow KB; Odontiadis J; Nobrega JN; Baker GB; George SR; Mamo D; Kapur S
    Psychopharmacology (Berl); 2008 Aug; 199(2):275-89. PubMed ID: 18521575
    [TBL] [Abstract][Full Text] [Related]  

  • 3. (-)-Stepholidine promotes proliferation and neuronal differentiation of rat embryonic striatal precursor cells in vitro.
    Guo H; Yu Y; Xing L; Jin GZ; Zhou J
    Neuroreport; 2002 Nov; 13(16):2085-9. PubMed ID: 12438931
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Functional reversal of (-)-Stepholidine analogues by replacement of benzazepine substructure using the ring-expansion strategy.
    Li W; Zhang L; Xu L; Yuan C; Du P; Chen J; Zhen X; Fu W
    Chem Biol Drug Des; 2016 Oct; 88(4):599-607. PubMed ID: 27232055
    [TBL] [Abstract][Full Text] [Related]  

  • 5. (-)-Stepholidine is a potent pan-dopamine receptor antagonist of both G protein- and β-arrestin-mediated signaling.
    Meade JA; Free RB; Miller NR; Chun LS; Doyle TB; Moritz AE; Conroy JL; Watts VJ; Sibley DR
    Psychopharmacology (Berl); 2015 Mar; 232(5):917-30. PubMed ID: 25231919
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dopamine D1 receptor agonist and D2 receptor antagonist effects of the natural product (-)-stepholidine: molecular modeling and dynamics simulations.
    Fu W; Shen J; Luo X; Zhu W; Cheng J; Yu K; Briggs JM; Jin G; Chen K; Jiang H
    Biophys J; 2007 Sep; 93(5):1431-41. PubMed ID: 17468175
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Involvement of dopamine D1 and D2 receptors in Fos immunoreactivity induced by stepholidine in both intact and denervated striatum of lesioned rats.
    Guo X; Ding YM; Hu JY; Jin GZ
    Life Sci; 1998; 62(25):2295-302. PubMed ID: 9651118
    [TBL] [Abstract][Full Text] [Related]  

  • 8. L-stepholidine, a natural dopamine receptor D1 agonist and D2 antagonist, inhibits heroin-induced reinstatement.
    Ma B; Yue K; Chen L; Tian X; Ru Q; Gan Y; Wang D; Jin G; Li C
    Neurosci Lett; 2014 Jan; 559():67-71. PubMed ID: 24269875
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dual actions of (-)-stepholidine on the dopamine receptor-mediated adenylate cyclase activity in rat corpus striatum.
    Dong ZJ; Guo X; Chen LJ; Han YF; Jin GZ
    Life Sci; 1997; 61(4):465-72. PubMed ID: 9244373
    [TBL] [Abstract][Full Text] [Related]  

  • 10. D(1)/D(2) receptor-targeting L-stepholidine, an active ingredient of the Chinese herb Stephonia, induces non-rapid eye movement sleep in mice.
    Qiu MH; Qu WM; Xu XH; Yan MM; Urade Y; Huang ZL
    Pharmacol Biochem Behav; 2009 Nov; 94(1):16-23. PubMed ID: 19604496
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of l-stepholidine on forebrain Fos expression: comparison with clozapine and haloperidol.
    Mo YQ; Jin XL; Chen YT; Jin GZ; Shi WX
    Neuropsychopharmacology; 2005 Feb; 30(2):261-7. PubMed ID: 15578005
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Characteristics of (-)-stepholidine on the firing activity of substantia nigral dopamine neurons after repeated reserpine treatment.
    Sun BC; Jin GZ
    Biol Signals; 1992; 1(6):331-8. PubMed ID: 1307933
    [TBL] [Abstract][Full Text] [Related]  

  • 13. (-)-Stepholidine: a potential novel antipsychotic drug with dual D1 receptor agonist and D2 receptor antagonist actions.
    Jin GZ; Zhu ZT; Fu Y
    Trends Pharmacol Sci; 2002 Jan; 23(1):4-7. PubMed ID: 11804640
    [No Abstract]   [Full Text] [Related]  

  • 14. L-Stepholidine, a naturally occurring dopamine D1 receptor agonist and D2 receptor antagonist, attenuates heroin self-administration and cue-induced reinstatement in rats.
    Yue K; Ma B; Chen L; Tian X; Ru Q; Gan Y; Wang D; Jin G; Li C
    Neuroreport; 2014 Jan; 25(1):7-11. PubMed ID: 24145772
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Synthesis and evaluation of C9 alkoxy analogues of (-)-stepholidine as dopamine receptor ligands.
    Madapa S; Gadhiya S; Kurtzman T; Alberts IL; Ramsey S; Reith M; Harding WW
    Eur J Med Chem; 2017 Jan; 125():255-268. PubMed ID: 27688181
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of (-)-stepholidine and D1 or D2 agonists on unit firing of globus pallidus in 6-hydroxydopamine-lesioned rats.
    Zhang XX; Zhu ZT; Jin GZ
    Life Sci; 1998; 63(7):537-44. PubMed ID: 9718079
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mechanisms involved in the vasorelaxant effect of (-)-stepholidine in rat mesenteric small arteries.
    Lei S; Orensanz LM; Mulvany MJ; Simonsen U
    Eur J Pharmacol; 1999 Jan; 365(2-3):193-204. PubMed ID: 9988103
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bifunctional peptidomimetic prodrugs of didanosine for improved intestinal permeability and enhanced acidic stability: synthesis, transepithelial transport, chemical stability and pharmacokinetics.
    Yan Z; Sun J; Chang Y; Liu Y; Fu Q; Xu Y; Sun Y; Pu X; Zhang Y; Jing Y; Yin S; Zhu M; Wang Y; He Z
    Mol Pharm; 2011 Apr; 8(2):319-29. PubMed ID: 21280612
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Preclinical pharmacokinetics of MK-0974, an orally active calcitonin-gene related peptide (CGRP)-receptor antagonist, mechanism of dose dependency and species differences.
    Roller S; Cui D; Laspina C; Miller-Stein C; Rowe J; Wong B; Prueksaritanont T
    Xenobiotica; 2009 Jan; 39(1):33-45. PubMed ID: 19219746
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Preclinical pharmacokinetics and in vitro metabolism of dasatinib (BMS-354825): a potent oral multi-targeted kinase inhibitor against SRC and BCR-ABL.
    Kamath AV; Wang J; Lee FY; Marathe PH
    Cancer Chemother Pharmacol; 2008 Mar; 61(3):365-76. PubMed ID: 17429625
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.